Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention
Recruiting
Phase 4
Interventional Study
ST-Segment Elevation Myocardial Infarction (STEMI)
No-Reflow Phenomenon
Coronary Slow Flow
Acute Myocardial Infarction
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 1,148 (estimated)
- Sponsor
- National Institute of Cardiovascular Diseases, Pakistan · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Primary objective of the study is to evaluate the impact of adenosine pre-medication on incidence of slow flow/no-reflow after primary percutaneous coronary intervention.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* All patients with acute STEMI undergoing primary PCI
* Patients of either sex, ≥18 years of age.
Exclusion Criteria:
* STEMI patients with cardiogenic shock at presentation
* Patients with heart block
* Allergy to adenosine
* Patients refuse to give consent for participation
Contacts